Status: Available
Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
This expanded access program provides investigational levacetylleucine to patients with Ataxia-Telangiectasia who are not eligible for clinical trials and have no satisfactory alternative therapies.
Trial details
Biological sex: AllType: Expanded AccessSponsor: IntraBio IncUpdated: Feb 24, 2026
Eligibility criteria
Patient has a genetically confirmed diagnosis of Ataxia-Telangiectasia, a rare a... [+4]
Patient is enrolled in or early withdrew participation from a clinical trial wit... [+4]